Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor

Folliculitis Companies

ID: MRFR/Pharma/2535-HCR
76 Pages
Satyendra Maurya
Last Updated: February 16, 2025
Folliculitis is a common skin condition characterized by the inflammation of hair follicles. While there isn't a specific company solely dedicated to treating folliculitis, there are pharmaceutical and skincare companies that produce products and medications aimed at managing and treating this condition. Additionally, dermatology-focused companies may have a range of products designed to address various skin conditions, including folliculitis. It's important to note that the availability of products and treatments may vary by region and regulatory approval.
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Folliculitis Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)5.81%
2024 Market Size$ 1.99 Billion
2025 Market Size$ 2.11 Billion
2035 Market Size$ 3.7 Billion
Key Players
Johnson & Johnson
GlaxoSmithKline
Bayer AG
Novartis AG
Pfizer Inc.
AbbVie Inc.
Opportunities
  • Impact of Lifestyle Changes
  • Advancements in Treatment Modalities
  • Increasing Incidence of Folliculitis

Top Industry Leaders in the Folliculitis Market

Folliculitis Key Companies
 
Latest Folliculitis Companies Update

Valeant Pharmaceuticals Launched Eliquis (apixaban) with an extended indication for the prevention of venous thromboembolism (VTE) in patients undergoing surgery for hip or knee replacement, potentially reducing folliculitis risk associated with anticoagulant therapy.

Galderma Announced positive Phase 3 data for its investigational topical antibiotic, BPX-121, for the treatment of gram-negative folliculitis, offering a potential new option for this challenging type of folliculitis.

La Roche-Posay Introduced a new line of skincare products specifically formulated for sensitive skin prone to folliculitis, addressing the need for gentle and effective solutions.

Stelara Pharma Received FDA approval for its new topical corticosteroid ointment, Clobexasol Propionate 0.05%, for the treatment of inflammatory skin conditions like eczema, potentially offering relief for folliculitis associated with these conditions.

List of Folliculitis Key Companies in the Market

  • AbbVie Inc. (US)
  • Allergan (Republic of Ireland)
  • AstraZeneca (UK)
  • CELGENE CORPORATION (US)
  • GlaxoSmithKline plc. (UK)
  • Johnson & Johnson Services Inc. (US)
  • Merck & Co. Inc. (US)
  • Pfizer Inc.(US)